[HTML][HTML] PHENIX: a comprehensive Python-based system for macromolecular structure solution
…, G Bunkóczi, VB Chen, IW Davis… - … Section D: Biological …, 2010 - scripts.iucr.org
Macromolecular X-ray crystallography is routinely applied to understand biological processes
at a molecular level. However, significant time and effort are still required to solve and …
at a molecular level. However, significant time and effort are still required to solve and …
Structure validation by Cα geometry: ϕ, ψ and Cβ deviation
Geometrical validation around the C is described, with a new C measure and updated
Ramachandran plot. Deviation of the observed C atom from ideal position provides a single …
Ramachandran plot. Deviation of the observed C atom from ideal position provides a single …
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
IW Davis, A Leaver-Fay, VB Chen, JN Block… - Nucleic acids …, 2007 - academic.oup.com
MolProbity is a general-purpose web server offering quality validation for 3D structures of
proteins, nucleic acids and complexes. It provides detailed all-atom contact analysis of any …
proteins, nucleic acids and complexes. It provides detailed all-atom contact analysis of any …
[BOOK][B] At risk: natural hazards, people's vulnerability and disasters
P Blaikie, T Cannon, I Davis, B Wisner - 2014 - taylorfrancis.com
The term 'natural disaster' is often used to refer to natural events such as earthquakes, hurricanes
or floods. However, the phrase 'natural disaster' suggests an uncritical acceptance of a …
or floods. However, the phrase 'natural disaster' suggests an uncritical acceptance of a …
[HTML][HTML] Enzalutamide in metastatic prostate cancer before chemotherapy
…, J Carles, S Chowdhury, ID Davis… - … England Journal of …, 2014 - Mass Medical Soc
Background Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in
men with metastatic castration-resistant prostate cancer in whom the disease has progressed …
men with metastatic castration-resistant prostate cancer in whom the disease has progressed …
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
CN Sternberg, ID Davis, J Mardiak… - Journal of clinical …, 2010 - ascopubs.org
Purpose Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth
factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double-…
factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double-…
ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules
We have recently completed a full rearchitecturing of the Rosetta molecular modeling program,
generalizing and expanding its existing functionality. The new architecture enables the …
generalizing and expanding its existing functionality. The new architecture enables the …
[HTML][HTML] Enzalutamide with standard first-line therapy in metastatic prostate cancer
Background Enzalutamide, an androgen-receptor inhibitor, has been associated with improved
overall survival in men with castration-resistant prostate cancer. It is not known whether …
overall survival in men with castration-resistant prostate cancer. It is not known whether …
MolProbity: structure validation and all-atom contact analysis for nucleic acids and their complexes
IW Davis, LW Murray, JS Richardson… - Nucleic acids …, 2004 - academic.oup.com
MolProbity is a general-purpose web service offering quality validation for three-dimensional
(3D) structures of proteins, nucleic acids and complexes. It provides detailed all-atom …
(3D) structures of proteins, nucleic acids and complexes. It provides detailed all-atom …
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Background Atezolizumab can induce sustained responses in metastatic urothelial carcinoma.
We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or …
We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or …